Adicet reports second quarter 2022 financial results and provides business updates

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta car t cell therapies for cancer, today reported financial results and operational highlights for the second quarter ended june 30, 2022. “during the second quarter of 2022, we made significant progress, achieving a number of clinical and regulatory milestones,” said chen schor, president and chief executive offic
ACET Ratings Summary
ACET Quant Ranking